Idiopathic Multicentric Castleman Disease following SARS-CoV-2 Vaccination
Idiopathic multicentric Castleman disease (iMCD) is a rare lymphoproliferative disorder. The preferred primary treatment for iMCD is siltuximab, an anti-interleukin-6 antibody (anti–IL-6). Chemotherapy is reserved for severe cases or when anti-IL-6 is unavailable. The increased IL-6 signaling in iMC...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2023-07-01
|
| Series: | Journal of Cancer Research and Practice |
| Subjects: | |
| Online Access: | https://journals.lww.com/10.4103/ejcrp.eJCRP-D-22-00035 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832591049504063488 |
|---|---|
| author | Chien-Yu Ker Hung-Wei Liu Yu-Chieh Su Pang-Yu Lai* |
| author_facet | Chien-Yu Ker Hung-Wei Liu Yu-Chieh Su Pang-Yu Lai* |
| author_sort | Chien-Yu Ker |
| collection | DOAJ |
| description | Idiopathic multicentric Castleman disease (iMCD) is a rare lymphoproliferative disorder. The preferred primary treatment for iMCD is siltuximab, an anti-interleukin-6 antibody (anti–IL-6). Chemotherapy is reserved for severe cases or when anti-IL-6 is unavailable. The increased IL-6 signaling in iMCD, increase in IL-6 after mRNA vaccines, and hyperactivation of IL-6 as a critical mediator in COVID-19 infection demonstrate a shared mechanism underlying inflammatory cytokine dysregulation. Herein, we present a case of iMCD after receiving a SARS-CoV-2 vaccination who was treated with traditional chemotherapy over the preferred siltuximab. |
| format | Article |
| id | doaj-art-a44c34f4e08543dba823341c811ae68a |
| institution | Kabale University |
| issn | 2311-3006 |
| language | English |
| publishDate | 2023-07-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Journal of Cancer Research and Practice |
| spelling | doaj-art-a44c34f4e08543dba823341c811ae68a2025-01-23T05:07:36ZengWolters Kluwer Medknow PublicationsJournal of Cancer Research and Practice2311-30062023-07-0110312112310.4103/ejcrp.eJCRP-D-22-00035Idiopathic Multicentric Castleman Disease following SARS-CoV-2 VaccinationChien-Yu KerHung-Wei LiuYu-Chieh SuPang-Yu Lai*Idiopathic multicentric Castleman disease (iMCD) is a rare lymphoproliferative disorder. The preferred primary treatment for iMCD is siltuximab, an anti-interleukin-6 antibody (anti–IL-6). Chemotherapy is reserved for severe cases or when anti-IL-6 is unavailable. The increased IL-6 signaling in iMCD, increase in IL-6 after mRNA vaccines, and hyperactivation of IL-6 as a critical mediator in COVID-19 infection demonstrate a shared mechanism underlying inflammatory cytokine dysregulation. Herein, we present a case of iMCD after receiving a SARS-CoV-2 vaccination who was treated with traditional chemotherapy over the preferred siltuximab.https://journals.lww.com/10.4103/ejcrp.eJCRP-D-22-00035castleman diseasechemotherapysars-cov-2 |
| spellingShingle | Chien-Yu Ker Hung-Wei Liu Yu-Chieh Su Pang-Yu Lai* Idiopathic Multicentric Castleman Disease following SARS-CoV-2 Vaccination Journal of Cancer Research and Practice castleman disease chemotherapy sars-cov-2 |
| title | Idiopathic Multicentric Castleman Disease following SARS-CoV-2 Vaccination |
| title_full | Idiopathic Multicentric Castleman Disease following SARS-CoV-2 Vaccination |
| title_fullStr | Idiopathic Multicentric Castleman Disease following SARS-CoV-2 Vaccination |
| title_full_unstemmed | Idiopathic Multicentric Castleman Disease following SARS-CoV-2 Vaccination |
| title_short | Idiopathic Multicentric Castleman Disease following SARS-CoV-2 Vaccination |
| title_sort | idiopathic multicentric castleman disease following sars cov 2 vaccination |
| topic | castleman disease chemotherapy sars-cov-2 |
| url | https://journals.lww.com/10.4103/ejcrp.eJCRP-D-22-00035 |
| work_keys_str_mv | AT chienyuker idiopathicmulticentriccastlemandiseasefollowingsarscov2vaccination AT hungweiliu idiopathicmulticentriccastlemandiseasefollowingsarscov2vaccination AT yuchiehsu idiopathicmulticentriccastlemandiseasefollowingsarscov2vaccination AT pangyulai idiopathicmulticentriccastlemandiseasefollowingsarscov2vaccination |